Opinion|Videos|September 23, 2024
The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System
Author(s)Jacqueline Nicholas, MD, MPH
Jacqueline Nicholas, MD, MPH, discusses the evolution of NMOSD pathophysiology understanding and the critical role of the complement system in its development.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has our understanding of the pathophysiology of NMOSD evolved over the years (Contentti 2021)?
- What is the role of the complement system in the pathophysiology of NMOSD?
Advertisement
Related to this article
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
The CHMP recommended approval of gefurulimab (Klygefa), a weekly self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
2
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
World Alzheimer Day: Notable Clinical Interviews From 2026
5